- Change in size of lesions:
  - Vismodegib: 21.4%
  - Non-vismodegib: 11.3%
  - Observation: 8.1%

- Change in number of lesions:
  - Vismodegib: 4.9%
  - Non-vismodegib: 8.1%
  - Observation: 14.8%

- Development of new BCCs:
  - Vismodegib: 28.6%
  - Non-vismodegib: 12.9%
  - Observation: 12.9%

- Progression from laBCC to mBCC:
  - Vismodegib: 3.3%
  - Non-vismodegib: 8.2%
  - Observation: 12.9%

- Other:
  - Vismodegib: 21.4%
  - Non-vismodegib: 21.4%
  - Observation: 21.4%